Cadila Pharmaceuticals

We accelerate the journey from molecule to market by delivering end-to-end CDMO solutions. We are present in APIs, Finished Dosage (OSD), Generics, Injectables, Biologics, and CRO segments, ensuring faster, safer, and smarter access to life-changing therapies worldwide.

74+

Years of Excellence

500+

Global Clients

100+

Countries Served

As a leader in pharmaceutical innovation, we serve as a trusted CDMO partner, helping global healthcare companies deliver life-saving therapies to patients more quickly, safely, and effectively.

End-to-End Support

Seamless support from preclinical research to full-scale commercialisation.

Manufacturing Facilities

We operate two advanced manufacturing facilities (Unit 1 & Unit 2), approved by the USFDA and EU-GMP.

Greenfield API Facility (DCS-Controlled)

Our newest greenfield API facility (Unit-3) is equipped with an advanced Distributed Control System (DCS).

Research Capabilities

Our R&D centre in India houses over 175 highly skilled scientists. It features Synthetic Chemistry Labs, Process Engineering Labs, Analytical Labs, and a Patent Cell.

CDMO Partner

Your trusted CDMO partner for end-to-end impact

We offer integrated CDMO solutions that streamline your path from concept to market. With advanced facilities, proven regulatory credibility, and a collaborative approach, we turn complex challenges into reliable, scalable outcomes.

We are committed to sustainable growth by adopting responsible environmental, social, and governance (ESG) practices. We aim to make a positive impact through our main initiatives.

downWhiteCurveArrow

Corporate Identification No : U24231GJ1991PLC015132

©2026 Cadila Pharmaceuticals. All rights reserved